This work is licensed under the Creative Commons Attribution 4.0 International License.
Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res 2015; 3: 436-443. 10.1158/2326-6066.CIR-15-0064EmensLAMiddletonG.The interplay of immunotherapy and chemotherapy: harnessing potential synergiesCancer Immunol Res2015343644310.1158/2326-6066.CIR-15-0064Open DOISearch in Google Scholar
Riaz N, Sherman E, Koutcher L, Shapiro L, Katabi N, Zhang ZG, et al. Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck. Am J Clin Oncol-Canc 2016; 39: 27-31. 10.1097/COC.0000000000000006RiazNShermanEKoutcherLShapiroLKatabiNZhangZGConcurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neckAm J Clin Oncol-Canc201639273110.1097/COC.0000000000000006Open DOISearch in Google Scholar
Izgi K, Iskender B, Sakalar C, Arslanhan A, Yuksek EH, Hizar E, et al. Effects of epirubicin and cisplatin against 4T1 breast cancer cells are enhanced by myrtucommulone-A. Anticancer Agents Med Chem 2016. [Epub ahead of print]. 10.2174/1871520616666160404110543IzgiKIskenderBSakalarCArslanhanAYuksekEHHizarEEffects of epirubicin and cisplatin against 4T1 breast cancer cells are enhanced by myrtucommulone-AAnticancer Agents Med Chem2016[Epub ahead of print]10.2174/1871520616666160404110543Open DOISearch in Google Scholar
Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res 2016; 106: 27-36. 10.1016/j.phrs.2016.01.001AmableL.Cisplatin resistance and opportunities for precision medicinePharmacol Res2016106273610.1016/j.phrs.2016.01.001Open DOISearch in Google Scholar
Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 2014; 5: e1257. 10.1038/cddis.2013.428GalluzziLVitaleIMichelsJBrennerCSzabadkaiGHarel-BellanASystems biology of cisplatin resistance: past, present and futureCell Death Dis20145e125710.1038/cddis.2013.428Open DOISearch in Google Scholar
Burger H, Zoumaro-Djayoon A, Boersma AWM, Helleman J, Berns EMJJ, Mathijssen RHJ, et al. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Brit J Pharmacol 2010; 159: 898-908. 10.1111/j.1476-5381.2009.00569.BurgerHZoumaro-DjayoonABoersmaAWMHellemanJBernsEMJJMathijssenRHJDifferential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)Brit J Pharmacol201015989890810.1111/j.1476-5381.2009.00569Open DOISearch in Google Scholar
Ciarimboli G. Membrane transporters as mediators of cisplatin side-effects. Anticancer Res 2014; 34: 547-50.CiarimboliG.Membrane transporters as mediators of cisplatin side-effectsAnticancer Res20143454750Search in Google Scholar
Larson CA, Blair BG, Safaei R, Howell SB. The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol 2009; 75: 324-30. 10.1124/mol.108.052381LarsonCABlairBGSafaeiRHowellSB.The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugsMol Pharmacol2009753243010.1124/mol.108.052381Open DOISearch in Google Scholar
Icsel C, Yilmaz VT, Ari F, Ulukaya E, Harrison WTA. trans-Dichloridopalladium (II) and platinum (II) complexes with 2-(hydroxymethyl)pyridine and 2-(2-hydroxyethyl)pyridine: synthesis, structural characterization, DNA binding and in vitro cytotoxicity studies. Eur J Med Chem 2013; 60: 386-94. 10.1016/j.ejmech.2012.12.002IcselCYilmazVTAriFUlukayaEHarrisonWTA.trans-Dichloridopalladium (II) and platinum (II) complexes with 2-(hydroxymethyl)pyridine and 2-(2-hydroxyethyl)pyridine: synthesis, structural characterization, DNA binding and in vitro cytotoxicity studiesEur J Med Chem2013603869410.1016/j.ejmech.2012.12.002Open DOISearch in Google Scholar
Kasparkova J, Marini V, Najajreh Y, Gibson D, Brabec V. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines. Biochemistry 2003; 42: 6321-32. 10.1021/bi0342315KasparkovaJMariniVNajajrehYGibsonDBrabecV.DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell linesBiochemistry20034263213210.1021/bi0342315Open DOISearch in Google Scholar
Martinez A, Lorenzo J, Prieto MJ, Font-Bardia M, Solans X, Aviles FX, et al. Influence of the position of substituents in the cytotoxic activity of trans platinum complexes with hydroxymethyl pyridines. Bioorg Med Chem 2007; 15: 969-79. 10.1016/j.bmc.2006.10.031MartinezALorenzoJPrietoMJFont-BardiaMSolansXAvilesFXInfluence of the position of substituents in the cytotoxic activity of trans platinum complexes with hydroxymethyl pyridinesBioorg Med Chem2007159697910.1016/j.bmc.2006.10.031Open DOISearch in Google Scholar
Najajreh Y, Perez JM, Navarro-Ranninger C, Gibson D. Novel soluble cationic trans-diaminedichloroplatinum (II) complexes that are active against cisplatin resistant ovarian cancer cell lines. J Med Chem 2002; 45: 5189-95.NajajrehYPerezJMNavarro-RanningerCGibsonD.Novel soluble cationic trans-diaminedichloroplatinum (II) complexes that are active against cisplatin resistant ovarian cancer cell linesJ Med Chem200245518995Search in Google Scholar
Quiroga AG. Understanding trans platinum complexes as potential antitumor drugs beyond targeting DNA. J Inorg Biochem 2012; 114: 106-12. 10.1016/j.jinorgbio.2012.06.002QuirogaAG.Understanding trans platinum complexes as potential antitumor drugs beyond targeting DNAJ Inorg Biochem20121141061210.1016/j.jinorgbio.2012.06.002Open DOISearch in Google Scholar
Ramos-Lima FJ, Moneo V, Quiroga AG, Carnero A, Navarro-Ranninger C. The role of p53 in the cellular toxicity by active trans-platinum complexes containing isopropylamine and hydroxymethylpyridine. Eur J Med Chem 2010; 45: 134-41. 10.1016/j.ejmech.2009.09.035Ramos-LimaFJMoneoVQuirogaAGCarneroANavarro-RanningerC.The role of p53 in the cellular toxicity by active trans-platinum complexes containing isopropylamine and hydroxymethylpyridineEur J Med Chem2010451344110.1016/j.ejmech.2009.09.035Open DOISearch in Google Scholar
Coluccia M, Natile G. Trans-platinum complexes in cancer therapy. Anticancer Agents Med Chem 2007; 7: 111-23.ColucciaMNatileG.Trans-platinum complexes in cancer therapyAnticancer Agents Med Chem2007711123Search in Google Scholar
Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs: targeted Pt (II) agents, nanoparticle delivery, and Pt (IV) prodrugs. Chem Rev 2016; 116: 3436-86. 10.1021/acs.chemrev.5b0059JohnstoneTCSuntharalingamKLippardSJ.The next generation of platinum drugs: targeted Pt (II) agents, nanoparticle delivery, and Pt (IV) prodrugsChem Rev201611634368610.1021/acs.chemrev.5b0059Open DOISearch in Google Scholar
Shahsavar F, Bozorgmehr M, Mirzadegan E, Abedi A, Lighvan ZM, Mohammadi F, et al. A novel platinum-based compound with preferential cytotoxic activity against a panel of cancer cell lines. Anticancer Agents Med Chem 2016; 16: 393-403.ShahsavarFBozorgmehrMMirzadeganEAbediALighvanZMMohammadiFA novel platinum-based compound with preferential cytotoxic activity against a panel of cancer cell linesAnticancer Agents Med Chem201616393403Search in Google Scholar
Ari F, Aztopal N, Icsel C, Yilmaz VT, Guney E, Buyukgungor O, et al. Synthesis, structural characterization and cell death-inducing effect of novel palladium (II) and platinum (II) saccharinate complexes with 2-(hydroxymethyl) pyridine and 2-(2-hydroxyethyl) pyridine on cancer cells in vitro. Bioorg Med Chem 2013; 21: 6427-34. 10.1016/j.bmc.2013.08.050AriFAztopalNIcselCYilmazVTGuneyEBuyukgungorOSynthesis, structural characterization and cell death-inducing effect of novel palladium (II) and platinum (II) saccharinate complexes with 2-(hydroxymethyl) pyridine and 2-(2-hydroxyethyl) pyridine on cancer cells in vitroBioorg Med Chem20132164273410.1016/j.bmc.2013.08.050Open DOISearch in Google Scholar
Cemazar M, Pipan Z, Grabner S, Bukovec N, Sersa G. Cytotoxicity of different platinum (II) analogues to human tumour cell lines in vitro and murine tumour in vivo alone or combined with electroporation. Anticancer Res 2006; 26: 1997-2002.CemazarMPipanZGrabnerSBukovecNSersaG.Cytotoxicity of different platinum (II) analogues to human tumour cell lines in vitro and murine tumour in vivo alone or combined with electroporationAnticancer Res20062619972002Search in Google Scholar
Grabner S, Cemazar M, Bukovec N, Sersa G. Syntheses and cytotoxicity of Pt (II) complexes with acyclovir. Acta Chim Slov 2006; 53: 153-8.GrabnerSCemazarMBukovecNSersaG.Syntheses and cytotoxicity of Pt (II) complexes with acyclovirActa Chim Slov2006531538Search in Google Scholar
Grabner S, Modec B, Bukovec N, Bukovec P, Cemazar M, Kranjc S, et al. Cytotoxic trans-platinum (II) complex with 3-hydroxymethylpyridine: synthesis, X-ray structure and biological activity evaluation. J Inorg Biochem 2016; 161: 40-51. 10.1016/j.jinorgbio.2016.04.031GrabnerSModecBBukovecNBukovecPCemazarMKranjcSCytotoxic trans-platinum (II) complex with 3-hydroxymethylpyridine: synthesis, X-ray structure and biological activity evaluationJ Inorg Biochem2016161405110.1016/j.jinorgbio.2016.04.031Open DOISearch in Google Scholar
Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, et al. Drug delivery systems: an updated review. Int J Pharm Investig 2012; 2: 2-11. 10.4103/2230-973X.96920TiwariGTiwariRSriwastawaBBhatiLPandeySPandeyPDrug delivery systems: an updated reviewInt J Pharm Investig2012221110.4103/2230-973X.96920Open DOISearch in Google Scholar
Kaur H, Desai SD, Kumar V, Rathi P, Singh J. Heterocyclic drug-polymer conjugates for cancer targeted drug delivery. Anticancer Agents Med Chem 2016; 16: 1355-77.KaurHDesaiSDKumarVRathiPSinghJ.Heterocyclic drug-polymer conjugates for cancer targeted drug deliveryAnticancer Agents Med Chem201616135577Search in Google Scholar
Neumann E, Schaeferridder M, Wang Y, Hofschneider PH. Gene-transfer into mouse lyoma cells by electroporation in high electric-fields. EMBO J 1982; 1: 841-5.NeumannESchaeferridderMWangYHofschneiderPH.Gene-transfer into mouse lyoma cells by electroporation in high electric-fieldsEMBO J198218415Search in Google Scholar
Cemazar M, Miklavcic D, Mir LM, Belchradek J, Bonnay M, Fourcault D, et al. Electrochemotherapy of tumours resistant to cisplatin: a study in a murine tumour model. Eur J Cancer 2001; 37: 1166-72. 10.1016/S09598049(01)00091-0CemazarMMiklavcicDMirLMBelchradekJBonnayMFourcaultDElectrochemotherapy of tumours resistant to cisplatin: a study in a murine tumour modelEur J Cancer20013711667210.1016/S09598049(01)00091-0Open DOISearch in Google Scholar
Kranjc S, Cemazar M, Grosel A, Pipan Z, Sersa G. Effect of electroporation on radiosensitization with cisplatin in two cell lines with different chemo- and radiosensitivity. Radiol Oncol 2003; 37: 101-7.KranjcSCemazarMGroselAPipanZSersaG.Effect of electroporation on radiosensitization with cisplatin in two cell lines with different chemo- and radiosensitivityRadiol Oncol2003371017Search in Google Scholar
Kranjc S; Cemazar M, Grosel A, Scancar J, Sersa G. Electroporation of LPB sarcoma cells in vitro and tumors in vivo increases the radiosensitizing effect of cisplatin. Anticancer Res 2003; 23: 275-81.KranjcSCemazarMGroselAScancarJSersaG.Electroporation of LPB sarcoma cells in vitro and tumors in vivo increases the radiosensitizing effect of cisplatinAnticancer Res20032327581Search in Google Scholar
Sersa G, Cemazar M, Miklavcic D. Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum (II) in mice. Cancer Res 1995; 55: 3450-5.SersaGCemazarMMiklavcicD.Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum (II) in miceCancer Res19955534505Search in Google Scholar
Cemazar M, Miklavcic D, Scancar J, Dolzan V, Golouh R, Sersa G. Increased platinum accumulation in SA-1 tumour cells after in vivo electrochemotherapy with cisplatin. Brit J Cancer 1999; 79: 1386-91.CemazarMMiklavcicDScancarJDolzanVGolouhRSersaG.Increased platinum accumulation in SA-1 tumour cells after in vivo electrochemotherapy with cisplatinBrit J Cancer199979138691Search in Google Scholar
Cemazar M, Tamzali Y, Sersa G, Tozon N, Mir L.M, Miklavcic D, et al. Electrochemotherapy in veterinary oncology. J Vet Intern Med 2008; 22: 826-31. 10.1111/j.1939-1676.2008.0117.xCemazarMTamzaliYSersaGTozonNMirL.MMiklavcicDElectrochemotherapy in veterinary oncologyJ Vet Intern Med2008228263110.1111/j.1939-1676.2008.0117.xOpen DOISearch in Google Scholar
Maglietti F, Tellado M, Olaiz N, Michinski S, Marshal, G. Combined local and systemic bleomycin administration in electrochemotherapy to reduce the number of treatment sessions. Radiol Oncol 2016; 50: 58-63. 10.1515/raon-2016-0015MagliettiFTelladoMOlaizNMichinskiSMarshalG.Combined local and systemic bleomycin administration in electrochemotherapy to reduce the number of treatment sessionsRadiol Oncol201650586310.1515/raon-2016-0015Open DOISearch in Google Scholar
Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol 2013; 39: 4-16. 10.1016/j.ejso.2012.08.016MaliBJarmTSnojMSersaGMiklavcicD.Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysisEur J Surg Oncol20133941610.1016/j.ejso.2012.08.016Open DOISearch in Google Scholar
Yarmush ML, Golberg A, Sersa G, Kotnik T, Miklavcic D. Electroporation-based technologies for medicine: principles, applications, and challenges. Annu Rev Biomed Eng 2014; 16: 295-320. 10.1146/annurev-bioeng-071813-1046221YarmushMLGolbergASersaGKotnikTMiklavcicD.Electroporation-based technologies for medicine: principles, applications, and challengesAnnu Rev Biomed Eng20141629532010.1146/annurev-bioeng-071813-104622Open DOISearch in Google Scholar
Cemazar M, Milacic R, Miklavcic D, Dolzan V, Sersa G. Intratumoral cisplatin administration in electrochemotherapy: antitumor effectiveness, sequence dependence and platinum content. Anticancer Drugs 1998; 9: 525-30.CemazarMMilacicRMiklavcicDDolzanVSersaG.Intratumoral cisplatin administration in electrochemotherapy: antitumor effectiveness sequence dependence and platinum contentAnticancer Drugs1998952530Search in Google Scholar
Sersa G, Teissie J, Cemazar M, Signori E, Kamensek U, Marshall Get al. Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer. Cancer Immunol Immunother 2015; 64: 1315-27. 10.1007/s00262-015-1724-2SersaGTeissieJCemazarMSignoriEKamensekUMarshallGElectrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransferCancer Immunol Immunother20156413152710.1007/s00262-015-1724-2Open DOISearch in Google Scholar
Markelc B, Sersa G, Cemazar M. Differential mechanisms associated with vascular disrupting action of electrochemotherapy: intravital microscopy on the level of single normal and tumor blood vessels. PloS One, 2013; 8: e59557. 10.1371/journal.pone.0059557MarkelcBSersaGCemazarM.Differential mechanisms associated with vascular disrupting action of electrochemotherapy: intravital microscopy on the level of single normal and tumor blood vesselsPloS One20138e5955710.1371/journal.pone.0059557Open DOISearch in Google Scholar
Belehradek JJ, Barski G, Thonier M. Evolution of cell-mediated antitumor immunity in mice bearing a syngeneic chemically induced tumor. Influence of tumor growth, surgical removal and treatment with irradiated tumor cells. Int J Cancer 1972; 9: 461-9.BelehradekJJBarskiGThonierM.Evolution of cell-mediated antitumor immunity in mice bearing a syngeneic chemically induced tumor. Influence of tumor growth surgical removal and treatment with irradiated tumor cellsInt J Cancer197294619Search in Google Scholar
Sedlar A, Dolinsek T, Markelc B, Prosen L, Kranjc S, Bosnjak M, et al. Potentiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sarcoma and carcinoma with different immunogenicity. Radiol Oncol 2012; 46: 302-11. 10.2478/v10019-012-0044-9SedlarADolinsekTMarkelcBProsenLKranjcSBosnjakMPotentiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sarcoma and carcinoma with different immunogenicityRadiol Oncol2012463021110.2478/v10019-012-0044-9Open DOISearch in Google Scholar
Hollis L.S, Amundsen AR, Stern EW. Chemical and biological properties of a new series of cis-diammineplatinum (II) antitumor agents containing three nitrogen donors: cis-[Pt(NH3)2(N-donor)Cl]+. J Med Chem 1989; 32: 128-36.HollisL.SAmundsenARSternEW.Chemical and biological properties of a new series of cis-diammineplatinum (II) antitumor agents containing three nitrogen donors: cis-[Pt(NH3)2(N-donor)Cl]+J Med Chem19893212836Search in Google Scholar
Leng M, Locker D, Giraud-Panis MJ, Schwartz A, Intini FP, Natile G, et al. Replacement of an NH3 by an iminoether in transplatin makes an antitumor drug from an inactive compound. Mol Pharmacol 2000; 58: 1525-35.LengMLockerDGiraud-PanisMJSchwartzAIntiniFPNatileGReplacement of an NH3 by an iminoether in transplatin makes an antitumor drug from an inactive compoundMol Pharmacol200058152535Search in Google Scholar
Perez JM, Kelland LR, Montero EI, Boxall FE, Fuertes MA, Alonso C, et al. Antitumor and cellular pharmacological properties of a novel platinum (IV) complex: trans-[PtCl2(OH)2(dimethylamine) (isopropylamine)]. Mol Pharmacol 2003; 63: 933-44.PerezJMKellandLRMonteroEIBoxallFEFuertesMAAlonsoCAntitumor and cellular pharmacological properties of a novel platinum (IV) complex: trans-[PtCl2(OH)2(dimethylamine) (isopropylamine)]Mol Pharmacol20036393344Search in Google Scholar
Cemazar M, Miklavcic D, Vodovnik L, Jarm T, Rudolf Z, Stabuc B, et al. Improved therapeutic effect of electrochemotherapy with cisplatin by intratumoral drug administration and changing of electrode orientation for electropermeabilization on EAT tumor model in mice. Radiol Oncol 1995; 29: 121-7.CemazarMMiklavcicDVodovnikLJarmTRudolfZStabucBImproved therapeutic effect of electrochemotherapy with cisplatin by intratumoral drug administration and changing of electrode orientation for electropermeabilization on EAT tumor model in miceRadiol Oncol1995291217Search in Google Scholar
Baharuddin P, Satar, N, Fakiruddin KS, Zakaria N, Lim MN, Yusoff NM, et al. Curcumin improves the efficacy of cisplatin by targeting cancer stem-like cells through p21 and cyclin D1-mediated tumour cell inhibition in non-small cell lung cancer cell lines. Oncol Rep 2016; 35: 13-25. 10.3892/or.2015.4371BaharuddinPSatarNFakiruddinKSZakariaNLimMNYusoffNMCurcumin improves the efficacy of cisplatin by targeting cancer stem-like cells through p21 and cyclin D1-mediated tumour cell inhibition in non-small cell lung cancer cell linesOncol Rep201635132510.3892/or.2015.4371Open DOISearch in Google Scholar
Lee JH, Chae JW, Kim JK, Kim HJ, Chung JY, Kim YH. Inhibition of cisplatin-resistance by RNA interference targeting metallothionein using reducible oligo-peptoplex. J Control Release 2015; 215: 82-90. 10.1016/j.jconrel.2015.07.015LeeJHChaeJWKimJKKimHJChungJYKimYH.Inhibition of cisplatin-resistance by RNA interference targeting metallothionein using reducible oligo-peptoplexJ Control Release2015215829010.1016/j.jconrel.2015.07.015Open DOISearch in Google Scholar
Chong SX, Au-Yeung SC, To KK. Monofunctional platinum (PtII) compounds - shifting the paradigm in designing new pt-based anticancer agents. Curr Med Chem 2016; 23: 1268-85. 10.2174/0929867323666160311114509ChongSXAu-YeungSCToKK.Monofunctional platinum (PtII) compounds - shifting the paradigm in designing new pt-based anticancer agentsCurr Med Chem20162312688510.2174/0929867323666160311114509Open DOISearch in Google Scholar
Igarashi K, Yamamoto N, Hayashi K, Takeuchi A, Miwa S, Odani A, et al. Effectiveness of two novel anionic and cationic platinum complexes in the treatment of osteosarcoma. Anticancer Agents Med Chem 2015; 15: 390-9.IgarashiKYamamotoNHayashiKTakeuchiAMiwaSOdaniAEffectiveness of two novel anionic and cationic platinum complexes in the treatment of osteosarcomaAnticancer Agents Med Chem2015153909Search in Google Scholar
Hudej R, Miklavcic D, Cemazar M, Todorovic V, Sersa G, Bergamo A, et al. Modulation of activity of known cytotoxic ruthenium (III) compound (KP418) with hampered transmembrane transport in electrochemotherapy in vitro and in vivo. J Membrane Biol 2014; 247: 1239-51. 10.1007/s00232-014-9696-2HudejRMiklavcicDCemazarMTodorovicVSersaGBergamoAModulation of activity of known cytotoxic ruthenium (III) compound (KP418) with hampered transmembrane transport in electrochemotherapy in vitro and in vivoJ Membrane Biol201424712395110.1007/s00232-014-9696-2Open DOISearch in Google Scholar
Hudej R, Turel I, Kanduser M, Scancar J, Kranjc S, Sersa G, et al. The Influence of electroporation on cytotoxicity of anticancer ruthenium (III) complex KP1339 in vitro and in vivo, Anticancer Res, 2010, 30 2055-63.HudejRTurelIKanduserMScancarJKranjcSSersaGThe Influence of electroporation on cytotoxicity of anticancer ruthenium (III) complex KP1339 in vitro and in vivoAnticancer Res201030205563Search in Google Scholar
Calvet CY, Famin D, Andre FM, Mir LM. Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. Oncoimmunology 2014; 3: e28131. 10.4161/onci.28131CalvetCYFaminDAndreFMMirLM.Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cellsOncoimmunology20143e2813110.4161/onci.28131Open DOISearch in Google Scholar
Cemazar M, Golzio M, Sersa G, Escoffre JM, Coer A, Vidic S, et al. Hyaluronidase and collagenase increase the transfection efficiency of gene electrotransfer in various murine tumors. Hum Gene Ther 2012; 23: 128-37. 10.1089/hum.2011.073CemazarMGolzioMSersaGEscoffreJMCoerAVidicSHyaluronidase and collagenase increase the transfection efficiency of gene electrotransfer in various murine tumorsHum Gene Ther2012231283710.1089/hum.2011.073Open DOISearch in Google Scholar
Bartel C, Bytzek AK, Scaffidi-Domianello YY, Grabmann G, Jakupec MA, Hartinger CG, et al. Cellular accumulation and DNA interaction studies of cytotoxic trans-platinum anticancer compounds. J Biol Inorg Chem 2012; 17: 465-74. 10.1007/s00775-011-0869-5BartelCBytzekAKScaffidi-DomianelloYYGrabmannGJakupecMAHartingerCGCellular accumulation and DNA interaction studies of cytotoxic trans-platinum anticancer compoundsJ Biol Inorg Chem2012174657410.1007/s00775-011-0869-5Open DOISearch in Google Scholar
Khazanov E, Barenholz Y, Gibson D, Najajreh Y. Novel apoptosis-inducing trans-platinum piperidine derivatives: synthesis and biological characterization. J Med Chem 2002; 45: 5196-204.KhazanovEBarenholzYGibsonDNajajrehY.Novel apoptosis-inducing trans-platinum piperidine derivatives: synthesis and biological characterizationJ Med Chem2002455196204Search in Google Scholar
Halamikova A, Heringova P, Kasparkova J, Intini FP, Natile G, Nemirovski A, et al. Cytotoxicity, mutagenicity, cellular uptake, DNA and glutathione interactions of lipophilic trans-platinum complexes tethered to 1-adamantylamine. J Inorg Biochem 2008; 102: 1077-89. 10.1016/j.jinorgbio.2007.12.015HalamikovaAHeringovaPKasparkovaJIntiniFPNatileGNemirovskiACytotoxicity, mutagenicity, cellular uptake DNA and glutathione interactions of lipophilic trans-platinum complexes tethered to 1-adamantylamineJ Inorg Biochem200810210778910.1016/j.jinorgbio.2007.12.015Open DOISearch in Google Scholar
Chowdhury MA, Huq F, Abdullah A, Beale P, Fisher K. Synthesis, characterization and binding with DNA of four planaramineplatinum (II) complexes of the forms: trans-PtL2Cl2 and [PtL3Cl]Cl, where L = 3-hydroxypyridine, 4-hydroxypyridine and imidazo(1,2-alpha)pyridine. J Inorg Biochem 2005; 99: 1098-112.ChowdhuryMAHuqFAbdullahABealePFisherK.Synthesis, characterization and binding with DNA of four planaramineplatinum (II) complexes of the forms: trans-PtL2Cl2 and [PtL3Cl]Cl, where L = 3-hydroxypyridine, 4-hydroxypyridine and imidazo(1,2-alpha)pyridineJ Inorg Biochem2005991098112Search in Google Scholar
Novakova O, Kasparkova J, Malina J, Natile G, Brabec V. DNA-protein crosslinking by trans-[PtCl2(E-iminoether)2]. A concept for activation of the trans geometry in platinum antitumor complexes. Nucleic Acids Res 2003; 31: 6450-60.NovakovaOKasparkovaJMalinaJNatileGBrabecV.DNA-protein crosslinking by trans-[PtCl2(E-iminoether)2]. A concept for activation of the trans geometry in platinum antitumor complexesNucleic Acids Res200331645060Search in Google Scholar
Richards AD, Rodger A. Synthetic metallomolecules as agents for the control of DNA structure. Chem Soc Rev 2007; 36: 471-83.RichardsADRodgerA.Synthetic metallomolecules as agents for the control of DNA structureChem Soc Rev20073647183Search in Google Scholar
Martincic A, Cemazar M, Sersa G, Kovac V, Milacic R, Scancar J. A novel method for speciation of Pt in human serum incubated with cisplatin, oxaliplatin and carboplatin by conjoint liquid chromatography on monolithic disks with UV and ICP-MS detection. Talanta 2013; 116: 141-8. 10.1016/j.talanta.2013.05.01MartincicACemazarMSersaGKovacVMilacicRScancarJ.A novel method for speciation of Pt in human serum incubated with cisplatin oxaliplatin and carboplatin by conjoint liquid chromatography on monolithic disks with UV and ICP-MS detectionTalanta2013116141810.1016/j.talanta.2013.05.01Open DOISearch in Google Scholar
Martincic A, Milacic R, Cemazar M, Sersa G, Scancar J. The use of CIM-DEAE monolithic chromatography coupled to ICP-MS to study the distribution of cisplatin in human serum. Anal Methods 2012; 4: 780-90. 10.1016/j.chroma.2014.10.054MartincicAMilacicRCemazarMSersaGScancarJ.The use of CIM-DEAE monolithic chromatography coupled to ICP-MS to study the distribution of cisplatin in human serumAnal Methods201247809010.1016/j.chroma.2014.10.054Open DOISearch in Google Scholar